GoAI
Get started
Wanjia Group Holdings Limited logo

Wanjia Group Holdings Limited

0401.HK

HKSEHealthcareMedical - Distribution

Open in GoAI

Latest quote

HK$0.133

−HK$0.003 · -2.21%

Aug 25, 2:21 PM HKT

0401.HK company overview

Regular session · HKT · Market data may be delayed.

Company profile

Company website

Wanjia Group Holdings Limited operates as an investment holding company, primarily engaged in the wholesale and distribution of pharmaceutical products across mainland China and Hong Kong. The firm also offers hemodialysis treatment and associated consultancy services. Its pharmaceutical goods are supplied to a diverse client base within Fujian province, including hospitals, various healthcare institutions, pharmaceutical retail chains, independent pharmacies, outpatient departments of community hospitals, healthcare service stations, and clinics. Established in 2004, the company is headquartered in Kowloon, Hong Kong.

Industry
Medical - Distribution
Sector
Healthcare
Headquarters
HK
CEO
Jia Jun Wang
Listed since
Oct 11, 2013
Employees
183

Market position

52-week range

Current HK$0.133

Open
HK$0.133
Previous close
HK$0.136
Volume
800K
0.66× average
Average volume
1.21M
Average daily volume
Market cap
150.11M HKD
Beta
1.34
Market reference 1
50-day average
HK$0.1195
+11.28% above average
200-day average
HK$0.1309
+1.63% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
69.37M HKD
P/E (TTM)
-7×
P/B (TTM)
1.16×
P/S (TTM)
0.73×
EV / EBITDA
-97.57×
Earnings yield
-10.94%
Free cash flow yield
-10.00%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
26.19%
Operating margin
-5.11%
Net margin
-7.04%
Return on equity
-11.79%
Return on assets
-7.44%
Return on invested capital
-7.48%

Financial health

Debt / equity
0.15×
Current ratio
2.22×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends42%15%-13%-40%Gross margin, FY2021: 35.03%Gross margin, FY2022: 32.78%Gross margin, FY2023: 30.23%Gross margin, FY2024: 31.14%Gross margin, FY2025: 26.86%Operating margin, FY2021: -30.60%Operating margin, FY2022: 2.58%Operating margin, FY2023: -21.78%Operating margin, FY2024: -2.53%Operating margin, FY2025: -4.41%Net margin, FY2021: -32.94%Net margin, FY2022: 1.05%Net margin, FY2023: -22.08%Net margin, FY2024: -4.09%Net margin, FY2025: -5.96%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 35.03%. Gross margin FY2022 32.78%. Gross margin FY2023 30.23%. Gross margin FY2024 31.14%. Gross margin FY2025 26.86%. Operating margin FY2021 -30.60%. Operating margin FY2022 2.58%. Operating margin FY2023 -21.78%. Operating margin FY2024 -2.53%. Operating margin FY2025 -4.41%. Net margin FY2021 -32.94%. Net margin FY2022 1.05%. Net margin FY2023 -22.08%. Net margin FY2024 -4.09%. Net margin FY2025 -5.96%.

Income trends

Revenue

165.39M HKD+2.28%

Operating income

−7.29M HKD-78.33%

Net income

−9.86M HKD-49.09%
Income trends across reported periods204.3M HKD111.46M HKD18.63M HKD−74.21M HKDRevenue, FY2021: 154.82M HKDRevenue, FY2022: 173.7M HKDRevenue, FY2023: 181.09M HKDRevenue, FY2024: 161.69M HKDRevenue, FY2025: 165.39M HKDOperating income, FY2021: −47.38M HKDOperating income, FY2022: 4.47M HKDOperating income, FY2023: −39.44M HKDOperating income, FY2024: −4.09M HKDOperating income, FY2025: −7.29M HKDNet income, FY2021: −51M HKDNet income, FY2022: 1.82M HKDNet income, FY2023: −39.98M HKDNet income, FY2024: −6.62M HKDNet income, FY2025: −9.86M HKDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 154.82M HKD. Revenue FY2022 173.7M HKD. Revenue FY2023 181.09M HKD. Revenue FY2024 161.69M HKD. Revenue FY2025 165.39M HKD. Operating income FY2021 −47.38M HKD. Operating income FY2022 4.47M HKD. Operating income FY2023 −39.44M HKD. Operating income FY2024 −4.09M HKD. Operating income FY2025 −7.29M HKD. Net income FY2021 −51M HKD. Net income FY2022 1.82M HKD. Net income FY2023 −39.98M HKD. Net income FY2024 −6.62M HKD. Net income FY2025 −9.86M HKD.
Metric (HKD)FY2025FY2024FY2023FY2022FY2021
Revenue165.39M HKD161.69M HKD181.09M HKD173.7M HKD154.82M HKD
Cost of goods sold120.96M HKD111.35M HKD126.35M HKD116.77M HKD100.59M HKD
Gross profit44.43M HKD50.35M HKD54.74M HKD56.94M HKD54.23M HKD
Selling, general, and administrative51.72M HKD55.79M HKD65.55M HKD59.38M HKD51.85M HKD
Operating expenses51.72M HKD54.44M HKD94.18M HKD52.46M HKD101.62M HKD
Interest income15K HKD35K HKD43K HKD33K HKD46K HKD
Interest expense1.02M HKD1.4M HKD1.71M HKD2.02M HKD1.31M HKD
Depreciation and amortization6.58M HKD8.22M HKD10.41M HKD11.92M HKD12.74M HKD
Operating income−7.29M HKD−4.09M HKD−39.44M HKD4.47M HKD−47.38M HKD
Net income−9.86M HKD−6.62M HKD−39.98M HKD1.82M HKD−51M HKD

Company facts updated Aug 25, 2026.

Earnings

Latest EPS result
0

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly EPS actual values compared with estimates0.040-0.03-0.07Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q2 '24Q4 '24
Q3 2022, reported Sep 30, 2022: actual -0.002, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Nov 24, 2022: actual -0.002, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 31, 2023: actual 0.004, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 27, 2023: actual 0.004, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 30, 2023: actual -0.003, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 28, 2023: actual -0.003, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 21, 2024: actual -0.033, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 25, 2024: actual 0.001, estimate —, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Estimates unavailable
Quarterly Revenue actual values compared with estimates48.55M45.67M42.79M39.91MQ3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q2 '24Q4 '24
Q3 2022, reported Sep 30, 2022: actual 45.07M HKD, estimate —, surprise —, Comparison unavailable. Q4 2022, reported Nov 24, 2022: actual 45.07M HKD, estimate —, surprise —, Comparison unavailable. Q1 2023, reported Mar 31, 2023: actual 41.78M HKD, estimate —, surprise —, Comparison unavailable. Q2 2023, reported Jun 27, 2023: actual 41.78M HKD, estimate —, surprise —, Comparison unavailable. Q3 2023, reported Sep 30, 2023: actual 46.69M HKD, estimate —, surprise —, Comparison unavailable. Q4 2023, reported Nov 28, 2023: actual 46.69M HKD, estimate —, surprise —, Comparison unavailable. Q2 2024, reported Jun 21, 2024: actual 43.86M HKD, estimate —, surprise —, Comparison unavailable. Q4 2024, reported Nov 25, 2024: actual 41.85M HKD, estimate —, surprise —, Comparison unavailable.

Corporate actions

Corporate action history

Stock split

Effective Jan 20, 2020

1:5

0401.HK peers

WuXi AppTec Co., Ltd. logo

2359.HK

WuXi AppTec Co., Ltd.

HK$204.2

+3.29%

Jiangsu Hengrui Pharmaceuticals Co.,Ltd logo

1276.HK

Jiangsu Hengrui Pharmaceuticals Co.,Ltd

HK$46.50

+0.09%

BeOne Medicines AG logo

6160.HK

BeOne Medicines AG

HK$223.2

+0.81%

WuXi Biologics (Cayman) Inc. logo

2269.HK

WuXi Biologics (Cayman) Inc.

HK$52.20

+7.41%

Hansoh Pharmaceutical Group Company Limited logo

3692.HK

Hansoh Pharmaceutical Group Company Limited

HK$31.58

+1.67%

Innovent Biologics, Inc. logo

1801.HK

Innovent Biologics, Inc.

HK$100.1

+0.60%

Continue in GoAI

Research 0401.HK

research.disclaimer